Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Prabashni Reddy"'
Publikováno v:
American Journal of Health-System Pharmacy. 79:1043-1046
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a939e10ca6bb0837f1e553bac2e07ece
https://doi.org/10.1093/ajhp/zxac080
https://doi.org/10.1093/ajhp/zxac080
Autor:
Kit Chan, Sarah E. Wakeman, Scott G. Weiner, Prabashni Reddy, Kimiyoshi Kobayashi, Rodd Kelly, Leonard D Young, Joshua Reynolds
Publikováno v:
Pain Med
Objectives To determine the effect of one-click integration of a state’s prescription drug monitoring program (PDMP) on the number of PDMP searches and opioid prescriptions, stratified by specialty. Methods Our large health system worked with the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5031b919f2cb1328dfe17b187a50aed6
https://doi.org/10.1093/pm/pnab051
https://doi.org/10.1093/pm/pnab051
Autor:
Nathan T. Connell, Nahal Beik, Gregory Piazza, Jean M. Connors, Katelyn W. Sylvester, Robert P. Giugliano, Prabashni Reddy
Publikováno v:
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine. 18:66-71
Andexanet alfa, a recombinant modified human "decoy" factor Xa (FXa) protein, is the first and only available antidote approved by the Food and Drug Administration to manage life-threatening or uncontrolled bleeding associated with the anti-Xa agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393b8f0a0336d8b62df8d27534d4d62b
https://doi.org/10.1097/hpc.0000000000000177
https://doi.org/10.1097/hpc.0000000000000177
Autor:
Prabashni Reddy, Foluso Agboola
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 23:1214-1218
In 2008, tbo-filgrastim was approved as a biosimilar in Europe and then approved in the United States by the FDA in 2012 as a biologic product with 1 similar indication to filgrastim. Because tbo-filgrastim was less expensive than filgrastim, and cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0a29e05324b8224d27ff2b8e6fe8d72
https://doi.org/10.18553/jmcp.2017.23.12.1214
https://doi.org/10.18553/jmcp.2017.23.12.1214
Publikováno v:
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine. 15:77-81
Idarucizumab (Praxbind), a humanized monoclonal antibody fragment was granted accelerated approval from the Food and Drug Administration in October 2015 as the first agent to reverse the effects of a novel oral anticoagulant. The drug is indicated fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aaa55693f0fcf1ddd5e1dfa634599ca
https://doi.org/10.1097/hpc.0000000000000076
https://doi.org/10.1097/hpc.0000000000000076
Publikováno v:
Journal of Pharmacy Practice. 30:9-16
The uptake of generic immunosuppressants lags comparatively to other drug classes, despite that the Food and Drug Administration (FDA) uses identical bioequivalence standards for all drugs. Transplant societies acknowledge the cost savings associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f2ee2cd43e8995322b635b60557d8e
https://doi.org/10.1177/0897190015585758
https://doi.org/10.1177/0897190015585758
Publikováno v:
American Journal of Health-System Pharmacy. 71:500-506
Palonosetron, a serotonin type 3–receptor (5-HT3) antagonist, was approved by the Food and Drug Administration (FDA) in 2003 for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) associated with initial and repeat courses of h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04ff4d070b953fdee486235e8b015aae
https://doi.org/10.2146/ajhp130394
https://doi.org/10.2146/ajhp130394
Publikováno v:
Utilization Management in the Clinical Laboratory and Other Ancillary Services ISBN: 9783319341972
With the focus in healthcare around improving quality while reducing costs the clinical and economic management around the use of medications in the inpatient and outpatient settings is critical. In September 2014, drug expenditures increased 12.2 %
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c37c3b0ea8bfdc9b44d59608f7fdd1e8
https://doi.org/10.1007/978-3-319-34199-6_25
https://doi.org/10.1007/978-3-319-34199-6_25
Autor:
Prabashni Reddy, Yu-Chen Yeh
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 32:559-579
Intravenous acetaminophen received United States Food and Drug Administration approval in November 2010 for the management of mild-to-moderate pain, management of moderate-to-severe pain with adjunctive opioid analgesics, and reduction of fever. Alth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::843b61572d31e9467b4cd4658b0f9f3d
https://doi.org/10.1002/j.1875-9114.2011.01085.x
https://doi.org/10.1002/j.1875-9114.2011.01085.x
Autor:
Jean M. Connors, Julie K. Atay, Geoffery K. Sherwood, David J. Kuter, Caroline Block, Avraham Almozlino, Nancy Berliner, Paul A. Arpino, Adolph M. Hutter, Prabashni Reddy, James I Weitzman, Robert P. Giugliano, Leslie G. Selbovitz, Michael A. Fischer, Gregory Piazza
Publikováno v:
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine. 10:117-127
Dabigatran etexilate is the first commercially available oral direct thrombin inhibitor. A single trial has studied patients at risk for stroke associated with nonvalvular atrial fibrillation; in this trial, dabigatran 150 mg twice a day met the crit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c43b8c3caa097d1b8b966720244a488
https://doi.org/10.1097/hpc.0b013e3182315c03
https://doi.org/10.1097/hpc.0b013e3182315c03